DYNAVAX TECHNOLOGIES Reports Fourth Quarter FY 2022 Earnings Results for December 31 2022.
March 20, 2023
Earnings Overview
On February 23 2023, DYNAVAX TECHNOLOGIES ($NASDAQ:DVAX) reported their financial results for the fourth quarter of Fiscal Year 2022, ending December 31 2022. Revenue for the quarter was USD 67.7 million, a drop of 32.1% compared to the same period in the previous year. Net income for the quarter amounted to USD 184.5 million, a decrease of 5.4% from the same quarter in the prior year.
Transcripts Simplified
Dynavax Technologies is advancing three adjuvanted vaccine programs: Tdap, Shingles, and Plague. The Tdap program recently completed a Phase 1 clinical trial with adult and adolescent safety showing the vaccine candidate was well-tolerated. The Shingles program is in Phase 1 with promising top line results showing high antibody and CD4 positive T cell vaccine response rates.
The Plague program is in Phase 2, evaluating immunogenicity, safety, and tolerability of an rF1V plague vaccine candidate adjuvanted with CpG 1018. Dynavax plans on submitting an abstract presenting full data from the Shingles program to an upcoming medical meeting and moving the program forward with a Phase 1/2 study in early 2024.
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Dynavax Technologies. More…
| Total Revenues | Net Income | Net Margin |
| 722.68 | 292.87 | 40.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Dynavax Technologies. More…
| Operations | Investing | Financing |
| 62.72 | -316 | 19.52 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Dynavax Technologies. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 985.85 | 404.84 | 4.55 |
Key Ratios Snapshot
Some of the financial key ratios for Dynavax Technologies are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 173.8% | – | 41.7% |
| FCF Margin | ROE | ROA |
| 7.7% | 34.8% | 19.1% |
Price History
The company’s stock opened at $10.9 and closed at $10.8, a 1.2% decrease from its previous closing price of $10.9. Overall, DYNAVAX TECHNOLOGIES’ fourth quarter earnings results were met with mixed reactions by investors. While its total revenue was slightly up from last year, its net income had decreased, indicating that the company still has a ways to go in order to become more profitable. Additionally, investments into product innovation and expansion have increased significantly, suggesting that DYNAVAX TECHNOLOGIES may have more success in the coming fiscal years. Live Quote…
Analysis
As a financial analysis platform, GoodWhale has performed a thorough analysis of DYNAVAX TECHNOLOGIES’s fundamentals. We have assigned a high risk rating to this stock in terms of both financial and business aspects. Our analysis has revealed three risk warnings in the balance sheet, cashflow statement and financial journal. These warnings indicate that investing in DYNAVAX TECHNOLOGIES carries considerable risk. If you would like to learn more about these risks and our full analysis, please register with us on goodwhale.com. More…
Peers
The market for Dynavax Technologies Corp is quite competitive. The company’s main competitors are Foresee Pharmaceuticals Co Ltd, Aeolus Pharmaceuticals Inc, and Kala Pharmaceuticals Inc. All of these companies are vying for a share of the market, and each has its own strengths and weaknesses. Dynavax Technologies Corp must keep an eye on all of its competitors in order to stay ahead in the market.
– Foresee Pharmaceuticals Co Ltd ($TPEX:6576)
Foresee Pharmaceuticals Co Ltd is a pharmaceutical company with a market cap of 8.77B as of 2022. The company has a Return on Equity of -22.28%. The company focuses on the development and commercialization of innovative drugs for the treatment of cancer and other diseases. The company’s products include F-76, a phase III clinical candidate for the treatment of ovarian cancer; and F-288, a phase II clinical candidate for the treatment of solid tumors. Foresee Pharmaceuticals Co Ltd was founded in 2007 and is headquartered in Taipei, Taiwan.
– Aeolus Pharmaceuticals Inc ($OTCPK:AOLS)
Aeolus Pharmaceuticals Inc is a pharmaceutical company that focuses on the development of treatments for a variety of conditions. The company’s market cap is $167.29k and its ROE is -383.62%. Aeolus Pharmaceuticals Inc’s main product is a treatment for a condition called idiopathic pulmonary fibrosis. The company is also developing treatments for other conditions, including cancer and Alzheimer’s disease.
– Kala Pharmaceuticals Inc ($NASDAQ:KALA)
Kala Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of eye diseases. The company’s lead product candidate, KPI-121, is a topical ocular formulation of loteprednol etabonate in development for the treatment of pain and inflammation associated with ocular surgery. Kala Pharmaceuticals Inc has a market cap of 7.69M as of 2022, a Return on Equity of 435.55%. The company’s focus on the development and commercialization of therapies for the treatment of eye diseases makes it a promising investment for those interested in the healthcare sector.
Summary
Investors looking to invest in Dynavax Technologies may be encouraged by their fourth quarter of Fiscal Year 2022 results. Total revenue was down 32.1% year-on-year to USD 67.7 million and net income was slightly down 5.4% to USD 184.5 million. Despite the decline in profits, Dynavax is still competitive in the market and could be an attractive investment opportunity for those seeking to capitalize on a well-performing company. While potential risks should be considered, investors may find that Dynavax Technologies offers a good balance of growth potential and stability.
Related Posts
Recent Posts
